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WHAT THIS PAPER ADDS
 Controversial results regarding the beneﬁt of carotid artery stenting (CAS) vs. endarterectomy (CEA) have challenged the
management of carotid artery disease in women.
 Our paper analyses the impact of gender on the in-hospital outcomes after both carotid interventions in New York State population.
 The results favour CEA for symptomatic women and show similar outcomes for CEA and CAS in asymptomatic women and in men
regardless of symptomatology.a r t i c l e i n f o
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Aim:We sought to better deﬁne the impact of sex on ‘in-hospital outcomes’ after carotid endarterectomy
(CEA) or stenting (CAS).
Methods: Hospital discharge databases for all carotid interventions obtained from the New York State
(NYS) Department of Health, Statewide Planning and Research Cooperative System between 2000 and
2009 (29,917 women, 39,771 men) were analysed. Mortality, stroke and composite event (stroke/death)
were compared between procedures after matching of patients by propensity score. Acute myocardial
infarction (AMI) was our secondary ‘end’ point.
Results: More than 90% of patients in both sexes were asymptomatic (27,439 women and 36,295 men).
Compared to men, asymptomatic women experienced more strokes after CEA (women: 1.38%, men:
1.16%, P ¼ 0.03) and higher AMI rates after both procedures (CEA; women: 0.75%, men: 0.51%, P ¼ 0.0009,
CAS; women: 0.96%, men: 0.28%, P ¼ 0.01). Between procedures, symptomatic women undergoing CAS
showed higher rates of mortality (CAS: 4.19%, CEA: 0.47%, P ¼ 0.01) and combined (stroke/mortality)
events (CAS: 12.09%, CEA: 6.05%, P ¼ 0.02). In all other cohorts, no statistically signiﬁcant difference was
found between the procedures.
Conclusions: Compared to CEA, CAS led to inferior in-hospital outcomes only in symptomatic women in
the last decade in NYS. Men and asymptomatic women showed comparable outcomes after both
procedures, whereas asymptomatic females were more prone to AMI after both interventions. These sex-
associated differences should be taken into account for the treatment of carotid artery disease.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Endovascular treatment of carotid artery disease has been sug-
gested as a potentially safe and less-invasive therapeutic alternativeascular Surgery, Mount Sinai
3, NY 10029, USA.
(A.G. Vouyouka).
ciety for Vascular Surgery. Publishto carotid endarterectomy (CEA).1 However, the merit of using
carotid artery angioplasty and stenting (CAS) has been questioned
in speciﬁc subgroups of patients.2,3 The role of gender in the
selection of the most effective carotid intervention remains
a matter of debate. Earlier reports comparing CEA or CAS failed
either to analyse the inﬂuence of gender or to show a clear beneﬁt
for men or women.4ed by Elsevier Ltd. All rights reserved.
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(VA Cooperative Trial, ACAS (Asymptomatic Carotid Atherosclerosis
Study) and ACST (Asymptomatic Carotid Surgery Trial))5e7 and
symptomatic patients (MRC European Carotid Surgery Trial (ECST)
and North American Symptomatic Carotid Endarterectomy Trial
(NASCET))8,9 showed marginal or decreased long-term beneﬁt in
women with at least 2-fold increase in the peri-operative compli-
cation rate as compared to men. Regarding endovascular therapy,
the SAPPHIRE (Stenting and Angioplasty with Protection in Patients
at High Risk for Endarterectomy) trial established long-term
equivalency of CAS compared to CEA, but did not look at the
effect of sex on outcome.10 Carotid stenting trialists’ collaboration
(CSTC) conducted a formal meta-analysis of EVA-3S (Endarterec-
tomy Versus Angioplasty in Patients with Symptomatic Severe
Carotid Stenosis),11 SPACE (Stent-Protected Angioplasty vs. Carotid
Endarterectomy)3 and ICSS (International Carotid Stenting Study)12
trials (symptomatic patients);2 they found that gender did not play
a role in CAS- or CEA- stroke and combined stroke and death rates.
In the CREST trial, on the other hand, both men and women had
higher rates of peri-procedural stroke after CAS and only men had
a lower rate of peri-procedural myocardial infarction (MI) after
endovascular treatment.13
The discrepancy between the CREST trial and the CSTC meta-
analysis continues to fuel the debate. The difference in MI risk
may, in part, be due to underreporting in the studies analysed by
meta-analysis, as ascertainment of this outcome was routinely
required only in CREST (Carotid Revascularization Endarterectomy
vs. Stenting Trial).13 Thus, to further inform the debate, we con-
ducted a retrospective observational population-based study to
determine the impact of sex on the outcomes of both carotid
interventions by reviewing the New York State (NYS) experience.
Patients and Methods
Data sources
The study used publicly available hospital discharge data sets
obtained from the NYS Department of Health, Statewide Planning
and Research Cooperative System (SPARCS) between 2000 and
2009 including a total of 10 years. This is a comprehensive data
reporting system established in 1979 as a result of cooperation
between the health-care industry and the government and was,
initially, created to collect information on discharges from all
hospitals in NYS. These databases currently collect patient level
details of patient characteristics (age, race and gender), diagnoses
and procedures, services and charges for every hospital discharge,
ambulatory surgery discharge and emergency department admis-
sion with approximately 100% coverage of in- or outpatient data.
NYS-administrative data sets contain a ‘present on admission’
(POA) ﬂag for each diagnosis. This was used to separate pre-existing
co-morbidities from complications that occurred during hospital-
isation.14 The POA ﬂag is important in measuring the provided
health-care quality and in receiving appropriate reimbursement for
services rendered.15
Patient cohort
Patients undergoing carotid revascularisation were identiﬁed
using the International Classiﬁcation of Diseases, 9th Revision,
Clinical Modiﬁcation (ICD-9-CM) procedure codes. For CAS proce-
dures, the ICD-9-CM code was 00.63 and for CEA procedures 38.12
in the primary- or secondary position. Hospitalisations for endo-
vascular repair of endocranial vessels (39.72) or carotid dissections
(443.21) were excluded. To prevent any bias from neurological
deﬁcits that may have arisen from concomitant surgicalprocedures, we excluded patients with concomitant major inter-
ventions (e.g., cardiac surgery) during the same hospitalisation.
Patients were stratiﬁed by gender: ‘males’ and ‘females’ and further
stratiﬁed by symptomatology: symptomatic and asymptomatic.
Deﬁnition of symptomatology and co-morbidities
‘Symptomatic presentation’ was deﬁned if the admitting or
primary diagnosis codes were for neurological symptoms that were
POA. The process of selection of symptomatic patients and symp-
tomatic codes has been described elsewhere.14 ‘Asymptomatic
patients’ were deﬁned as those without these POA-ﬂagged
diagnoses.
Co-morbidities
A modiﬁed Elixhauser coding algorithm was used to deﬁne
baseline co-morbidities according to speciﬁcations of Quan et al.16
Only POA diagnoses were included as co-morbidities. The codes for
all co-morbidities have been described elsewhere.14
Study design
This is a retrospective cohort study with ‘primary endpoints’ of
in-hospital mortality, postoperative stroke and the composite end
point of stroke or death. Acute MI was our ‘secondary endpoint’.
Deﬁnition of end points
‘Postoperative stroke’ was deﬁned if a discharge had the ICD-9-
CM code for postoperative stroke (997.02) or if any of the following
diagnoses codes were not present on admission and were observed
and documented during hospitalisation: hemiplegia (342.90),
intracerebral haemorrhage (431), cerebral embolism with infarc-
tion (434.11), cerebral artery occlusion with infarction (434.91),
aphasia (784.3), surgical complications from central nervous
system (997.01), acute cerebrovascular insufﬁciency (437.1), cere-
bral vascular accident (436) and retinal arterial occlusions
(362.30e34 and 362.84). Transient cerebral ischaemia (435.8 and
435.9) was excluded. ‘Acute MI’ was deﬁned if a discharge had the
code ‘410’ in any position.
Statistical analysis
Statistical analysis was performed using the SAS software (SAS
Institute Inc, Cary, NC, USA). Conﬁdence intervals for rates were
calculated using normal approximation to the binomial distribu-
tion. Propensity scores were used to match cohort and create eight
balanced groups for comparative analysis (males vs. females for
each procedure and CAS vs. CEA for each sex). In the respective
logistic regression analysis, gender or procedures were set as
dependent variables, while independent variables were patients’
demographics, co-morbidities and hospital annual volume in CAS
and CEA reﬂecting operators’ experience and learning curve
(Table 1). The cut point for the hospital volume was 17 CAS
procedures and 33 CEA procedures.14 The ﬁt of logistic regression
model was assessed through the concordance index17 and cali-
bration through the HosmereLemeshow test. Female and male
hospitalisations were matched 1:1 using individual propensity
scores by the greedy match algorithm.18 We calculated the stand-
ardised ratio to assess the matching between cohorts. Differences
between matched pairs were evaluated using the paired t-test for
continuous variables and the McNemar test was performed for
binary data. Statistical signiﬁcance was conﬁrmed by values of
P < 0.05.
Table 1
Patients’ characteristics and comorbidities on admission in 69,688 females and
males undergoing either carotid endarterectomy or stenting in New York State
between 2000 and 2009.
Parameter Females
N ¼ 29,917
Males
N ¼ 39,771
P-value
Symptomatic 2478(8.3%) 3476(8.7%) 0.03
Mean age, years 71.8 71.2 <0.0001
Race
White 25,250(84.4%) 34,124(85.8%) <0.0001
Black 1286(4.3%) 955(2.4%)
Cardiac comorbidities <0.0001
Arterial Hypertension 22,258(74.4%) 28,078(70.6%) 0.95
Congestive heart failure 1855(6.2%) 2466(6.2%) <0.0001
Cardiac arrhythmias 2663(8.9%) 5051(12.7%) <0.0001
Valvular disease 2214(7.4%) 2386(6.0%) <0.0001
Coronary artery disease 10,052(33.6%) 11,778(44.7%)
Pulmonary comorbidities 0.31
Emphysema 509(1.7%) 636(1.6%) <0.0001
Other pulmonary 5086(17%) 5567(14%) 0.70
Neurological disorders 449(1.5%) 597(1.5%) 0.12
Diabetes mellitus 8437(28.7%) 11,414(28.7%) 0.0002
Dyslipidemia 13,522(45.2%) 17,420(43.8%) <0.0001
Obesity 1047(3.5%) 915(2.3%) <0.0001
Renal failure 987(3.3%) 1551(3.9%) 0.67
Dialysis 90(0.3%) 119(0.3%) <0.0001
Neck cancer 90(0.3%) 239(0.6%) 0.02
Metastatic cancer 60(0.2%) 80(0.2%)
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Between 2000 and 2009, we identiﬁed 69,688 hospitalisations
in NYS for carotid intervention (CEA or CAS). Among these hospi-
talisations, 29,917 (43%) were for women and 39,771 (57%) for men.
Table 1 presents the analysed co-morbid conditions. The frequencyFigure 1. Proportions per 1000 capita hospitalisations show the trends of hospitalisation
Asymptomatic males and (D) Symptomatic males in NYS (Note: Before October 2004, no dof emergent procedures (deﬁned by emergent admission type
(code 1) in the in the SPARCS database) in the two cohorts was
identical (5623 females (18.8%) vs. 7486 males (18.8%)).
Use of CAS and CEA procedure by gender and symptomatology
Within females, 27,843 patients (93%) underwent CEA and 2074
(7%) CAS. The same proportion was found within men; 36,445
(92%) patients underwent CEA and 3326 (8%) CAS. With reference
to symptomatology, only 8% of women (2478 patients) and 9% of
men (3476 patients) were symptomatic. More speciﬁcally, in the
female cohort, 12% (250 patients) of all CAS and 8% (2228 patients)
of all CEA were performed in symptomatic patients. Similarly in
men, 12% (387 patients) of all CAS and 9% (3089 patients) of all CEA
procedures were performed for symptomatic disease. The mean
time for the performance of CAS or CEA in symptomatic patients
was the 4th day after hospitalisation, while the mean length of stay
(LOS) amounted to 8 days (median LOS: 5 days) for CEA and 7 days
(median LOS: 5 days) for CAS in symptomatic cohorts.
Trends inper capita hospitalisations for each genderwith respect
to symptomatology and carotid procedure are illustrated in Fig. 1.
The proportion of carotid interventions in asymptomatic women
slightly decreased during the study period, whereas it remained
stable for symptomatic women. The same trends were observed
in asymptomatic and symptomatic male counterparts respectively.
Comparison of outcomes of CAS vs. CEA depending on sex and
symptomatology
Comparison of outcomes was done for matched groups. Within
27,439 asymptomatic females (1824 CAS/25,615 CEA), we matcheds and carotid procedures for (A) Asymptomatic females (B) Symptomatic females (C)
edicated ICD-9-CM procedural code for CAS existed).
Table 2
Primary and secondary endpoints comparing carotid artery stenting (CAS) vs. e
endarterectomy (CEA) between propensity-matched asymptomatic cohorts for each
gender.
Asymptomatic females
Endpoints CAS (N ¼ 1754) CEA (N ¼ 1754) P
Primary
In-hospital
mortality
0.68% (95%CI:0.30e1.07) 0.29% (95%CI:0.04e0.53) 0.09
Stroke 2.17% (95%CI:1.15e2.85) 1.77% (95%CI:1.15e2.38) 0.39
Stroke/death 2.57% (95%CI:1.82e3.31) 1.94% (95%CI:1.29e2.54) 0.20
Secondary
Acute myocardial
infarction
0.79% (95%CI:0.38e1.21) 0.74% (95%CI: 0.34e1.14) 0.85
MedianeMean
length of stay
(days)
1/3.0 (2.7e3.3) 2/3.8 (3.5e4.2) <0.001
Asymptomatic males
Endpoints CAS (N ¼ 2792) CEA (N ¼ 2792) P
Primary
In-hospital
mortality
0.71% (95%CI:0.40e1.03) 0.50% (95%CI:0.24e0.76) 0.30
Stroke 2.11% (95%CI:1.58e2.65) 1.61% (95%CI:1.14e2.08) 0.17
Stroke/death 2.54% (95%CI:1.96e3.13) 1.89% (95%CI:1.39e2.40) 0.10
Secondary
Acute myocardial
infarction
0.43% (95%CI:0.19e0.67) 0.57% (95%CI: 0.29e0.85) 0.45
Median-Mean
length of stay
(days)
1/2.6 (2.4e2.8) 1/3.2 (2.9e3.5) <0.001
Table 4
Primary and secondary endpoints comparing asymptomatic females vs. males
between propensity-matched cohorts for each procedure.
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reduction (SR) for the smallest group). In 2478 symptomatic
females (250 CAS/2228 CEA), 215 CAS (86%) and 215 CEA (10%)
were matched (SR: 14%). In 36,295 asymptomatic males (2939 CAS/
33,356 CEA), we matched 2792 CAS (95%) with 2792 CEA (8%) (SR:
5%). Finally, in 3476 symptomatic males (387 CAS/3089 CEA), 341Table 3
Primary and secondary endpoints comparing carotid artery stenting (CAS) vs. e
endarterectomy (CEA) between propensity-matched symptomatic cohorts for each
gender.
Symptomatic females
Endpoints CAS (N ¼ 215) CEA (N ¼ 215) P
Primary
In-hospital
mortality
4.19% (95%CI:1.49e6.20) 0.47% (95%CI:-0.45e1.38) 0.01
Stroke 9.30% (95%CI:5.39e13.22) 5.58% (95%CI:2.49e8.67) 0.12
Stroke/Death 12.09% (95%CI:7.70e16.49) 6.05% (95%CI:2.83e9.26) 0.02
Secondary
Acute myocardial
infarction
1.40% (95%CI:0.19e2.98) 1.86% (95%CI: 0.04e3.68) 0.71
MedianeMean
length of stay
(days)
6/7.8 (6.8e8.8) 5/7.1 (6.2e7.9) 0.57
Symptomatic males
Endpoints CAS (N ¼ 341) CEA (N ¼ 341)
Primary
In-hospital
mortality
2.05% (95%CI:0.54e3.57) 1. 17% (95%CI:0.02e2.32) 0.37
Stroke 5.87% (95%CI:3.36e8.37) 4.40% (95%CI:2.21e6.59) 0.40
Stroke/Death 7.04% (95%CI:4.31e9.77) 4.99% (95%CI:2.66e7.30) 0.27
Secondary
Acute myocardial
infarction
1.76% (95%CI:0.36e3.16) 1.17% (95%CI: 0.02e2.30) 0.53
MedianeMean
length of stay
(days)
5/7.3 (6.3e8.2) 5/6.9 (6.1e7.7) 0.58CAS (88%) with 341 CEA (11%) werematched (SR: 12%). Tables 2 and
3 present the numeric results of the primary and secondary end
points as well as the median and mean LOS for asymptomatic and
symptomatic patients, respectively.
Summing up, CAS was comparable to CEA in asymptomatic
patients and symptomatic men for each primary end point. In
symptomatic women, CAS was inferior to CEA with considerably
high rates of mortality (CAS: 4.19% vs. CEA: 0.47%, P ¼ 0.01) and
composite events (CAS: 12.09% vs. CEA: 6.05%%, P ¼ 0.02),
Regarding acuteMI, both procedures were comparable, irrespective
of sex or symptomatology.
Comparison of outcomes in females vs. males for each carotid
procedure in asymptomatic and symptomatic groups
Within 4763 CAS for asymptomatic patients (2939 men/1824
women), 1773 men (60%) with 1773 women (97%) were matched
(SR: 3%). In 637 CAS for symptomatic sexes (387 men/250 women),
we matched 233 men (60%) and 233 women (93%) (SR: 7%).
Regarding CEA for asymptomatic patients, within 58 971 patients
(33 356 men/25 615 women), we matched 24 251 men (73%) with
24 251 women (95%) (SR: 5%). In 5317 symptomatic CEA recipients
(3089 men/2228 women), 2164 men (70%) and 2164 women (97%)
were matched (SR: 3%). Tables 4 and 5 summarise the numeric
results of the primary and secondary end points as well as themean
and median LOS for asymptomatic and symptomatic patients,
respectively.
We observed no signiﬁcant differences between sexes (asymp-
tomatic or symptomatic) undergoing CAS for all primary end
points. On the other hand, CEA led to higher rates of stroke in
asymptomatic women (women: 1.38% vs. men: 1.16%, P ¼ 0.03),
while there was no sex-related difference in symptomatic patients.Carotid artery stenting
Endpoints Asymptomatic
females (N ¼ 1773)
Asymptomatic
males (N ¼ 1773)
P
Primary
In-hospital
mortality
0.79%
(95%CI:0.38e1.20)
0.79%
(95%CI:0.38e1.20)
1.00
Stroke 2.14%
(95%CI:1.47e2.82)
1.97%
(95%CI:1.33e2.62)
0.73
Stroke/death 2.65%
(95%CI:1.90e3.40)
2.43%
(95%CI:1.71e3.14)
0.67
Secondary
Acute myocardial
infarction
0.96%
(95%CI:0.50e1.41)
0.28%
(95%CI: 0.03e0.53)
0.01
MedianeMean
length of stay
(days)
1/3.1 (2.8e3.4) 1/2.7 (2.4e3.0) <0.0001
Carotid endarterectomy
Endpoints Asymptomatic females
(N ¼ 24,521)
Asymptomatic males
(N ¼ 24,521)
P
Primary
In-hospital
mortality
0.47%
(95%CI:0.39e0.56)
0.48%
(95%CI:0.38e0.55)
0.95
Stroke 1.38%
(95%CI:1.24e1.53)
1.16%
(95%CI:1.02e1.29)
0.03
Stroke/death 1.65%
(95%CI:1.49e1.81)
1.65%
(95%CI:1.49e1.81)
0.06
Secondary
Acute myocardial
infarction
0.75%
(95%CI:0.64e0.85)
0.51%
(95%CI:0.42e0.60)
0.0009
MedianeMean
length of stay
(days)
1/3.1 (3.0e3.2) 1/2.8 (2.7e2.8) <0.0001
Table 5
Primary and secondary endpoints comparing symptomatic females vs. males between
propensity-matched cohorts for each procedure.
Carotid artery stenting
Endpoints Symptomatic
females (N ¼ 233)
Symptomatic
males (N ¼ 233)
P
Primary
In-hospital
mortality
4.29%
(95%CI:1.67-6. 91)
3.86%
(95%CI:1.37e6.36)
0.83
Stroke 8.15%
(95%CI:4.61e11.69)
5.58%
(95%CI:2.61e8.55)
0.29
Stroke/death 10. 73%
(95%CI:6.73e14.73)
8.58%
(95%CI:4.96e12.21)
0.46
Secondary
Acute myocardial
infarction
1.72%
(95%CI:0.04e3.40)
2.58%
(95%CI: 0.53e4.62)
0.53
MedianeMean
length of stay
(days)
6/8.0 (7.1e9.0) 5/8.1 (6.8e9.3) 0.40
Carotid endarterectomy
Endpoints Symptomatic
females (N ¼ 2184)
Symptomatic
males (N ¼ 2184)
P
Primary
In-hospital
mortality
0.74%
(95%CI:0.38e1.10)
1.06%
(95%CI:0.63e1.50)
0.25
Stroke 4.02%
(95%CI:3.19e4.85)
3.60%
(95%CI:2.82e4.39)
0.48
Stroke/death 4.44%
(95%CI:3.57e5.30)
4.11%
(95%CI:3.28e4.95)
0.60
Secondary
Acute myocardial
infarction
1.29%
(95%CI:0.82e1.77)
0.97%
(95%CI: 0.56e1.38)
0.32
MedianeMean
length of stay
(days)
5/7.1 (6.8e7.5) 5/6.7 (6.4e7.1) 0.006
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between different sexes and procedure cohorts, asymptomatic
women compared to asymptomatic men had statistically signiﬁ-
cant higher MI rates after CAS (women: 0.96% vs. men: 0.28%,
P ¼ 0.01) or CEA (women: 0.75% vs. men: 0.51%, P ¼ 0.0009). In
symptomatic patients, MI rates were statistically comparable
between sexes after either procedure.
Discussion
In our study, CAS and CEA showed comparable outcomes in
asymptomatic men and women and in symptomatic men.
However, in symptomatic women, CAS showed clearly inferior
outcomes in mortality and composite events, with remarkably high
rates of combined stroke and death (12.09%). In fact, female CAS
recipients were the cohort most prone to adverse events in NYS
during the last decade with a twofold increase of stroke/death rates
compared to CEA recipients. Moreover, the stroke rates in symp-
tomatic women undergoing CAS, despite statistical insigniﬁcance
compared to CEA, were numerically quite higher compared to the
stroke rate after CEA (CAS: 9.30% vs. CEA: 5.58%). Additional co-
morbidities or worse overall condition of the symptomatic
patients could possibly explain the high mortality rates, and this is
also reﬂected in the considerably longer LOS in symptomatic
cohorts (6e9 days). However, the delayed performance of the
procedures after the beginning of the hospitalisation (mean time:
4th day) could also explain the lengthy LOS in symptomatic
cohorts.14 Of note, only 39% of the CAS procedures and 38% of the
CEA procedures were done in symptomatic patients on the ﬁrst day
of hospitalisation in this database.
Historical large CEA-randomised trials were not designed for
sex-subgroup analysis. Most of the information concerning womenwas derived from either post hoc-analysis or trials, where therewas
an underrepresentation of women.13 For instance, initially NASCET
and ECST did not report any sex-subgroup analysis.8,9 In symp-
tomatic women, 30-day stroke and death rates with CEA reached
7.6% in NASCET and 11.1% in ECST.8,9 In symptomatic men, NASCET
showed a 5.9% 30-day stroke and mortality rate, whereas ECST
reported 6.4%.8,9 For asymptomatic patients, ACAS and ACST
reported the same 30-day composite stroke/death rates for men
and women (3.6%) and either no difference or marginal difference
in the 5-year beneﬁt for reduction of stroke risk after CEA. However,
as emphasised before, these gender-related results are difﬁcult to
interpret due to signiﬁcant design limitations.5,6 In any case,
women had higher perioperative adverse events (i.e., stroke and
combined stroke and death) rates than men.
When it comes to carotid stent trials, the impact of sex on the
procedural outcomes is not well identiﬁed.10,19 A meta-analysis of
EVA-3S, SPACE and ICSS trials, conducted to better deﬁne gender-
associated differences in symptomatic cohorts, had results similar
to ours: surgical risk for the composite event of stroke or death was
higher in women than in men (6.9% vs. 5.4%), whereas the risks of
stenting were unaffected by gender (women: 8.5% vs. men: 9.0%).2
In our study, which analysed only in-hospital outcomes, asymp-
tomatic women did worse only after CEA, and symptomatic women
had equivalent immediate outcomes after CEA and CAS as
compared to men. This marginal difference or no difference in
immediate outcomes between men and women after carotid
procedures is quite different from what was historically indicated
by large-scale trials but agrees with the results of CSTC meta-
analysis.2 More importantly, our data agree with ﬁndings from the
CREST trial derived from the analysis of the female cohort. Indeed,
the CREST trial, although it did not show any gender-related
difference, in separate analysis focussed on 832 enrolled women,
CEA was superior to CAS in symptomatic women (as in our study)
based on lower rates of peri-procedural stroke (CAS: 7.5% vs. CEA:
2.7%, P ¼ 0.03) or the composite stroke, MI or death (CAS: 9.2% vs.
CEA: 4.0%, P ¼ 0.03).13 In addition, similar to our observations,
asymptomatic women in the CREST trial showed comparable rates
of stroke (CAS: 3.3% vs. CEA: 1.6%, P¼ 0.28) and composite events of
stroke or death (CAS: 3.3% vs. CEA: 1.6%, P ¼ 0.28).13
In the existing literature, a number of risk factors (vessel
diameter, plaque composition, sensitivity for anti-platelet therapy,
sex hormones, etc.) have been suggested as potential mechanisms
for the different outcomes betweenmen andwomen after CEA.20 In
theory, women should also do well after CAS or at least should not
have worse outcomes than men based on the following consider-
ations: The literature suggests that in women the atherosclerotic
plaque is relatively stable, female carotid arteries are higher-
velocity vessels with increased outﬂow/inﬂow ratio and women
tend to have relatively localised lesions compared to men.20e23
Such factors are usually associated with favourable immediate
and long-term outcomes after CAS. On the other hand though,
women tend to have atherosclerotic plaque mainly distributed in
the common carotid as opposed to the proximal internal carotid
artery, which is usually seen in men.4 This may cause challenges
when the lesions are traversed during CAS especially in symp-
tomatic patients who have unstable and friable plaque. In fact,
symptomatic women had signiﬁcantly larger particles captured by
the cerebral protection device during CAS compared to asymp-
tomatic suggesting higher embolic potential in symptomatic
women compared to their asymptomatic counterparts during
stenting.22
A notable ﬁnding in our study was that 92% of the carotid
procedures (63,734 out of 69,688 patients) were performed in
asymptomatic patients. Interestingly, the same trend was shown
for the US national use of carotid procedures in a recent publication
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although in this study the deﬁnition of symptomatic patients was
notwell described, as POA ﬂags for each diagnosis (they are not part
of the NIS database) were missing.24,25 Similar results were found
in the analysis of the peri-procedural outcomes after carotid
interventions in the NIS for the year 2005 by McPhee et al.26 All
these databases reﬂect real-world medical practice as compared to
databases from randomised controlled trials that usually include
tertiary care and university centres only, and these ﬁndings prob-
ably suggest that medical practice in the community is rather
different from that in large centres.
Rockman et al.24 also reported comparable rates of peri-
procedural stroke for both carotid interventions for symptomatic
and asymptomatic patients. Similar to our ﬁndings, they reported
a 2-fold increase in stroke in symptomatic women undergoing CAS
compared to those who had CEA (6.2% vs. 3.4%, P ¼ 0.1). In contrast
to what we found, in this study, asymptomatic women experienced
signiﬁcantly higher stroke rates after CAS (2.1%) than CEA (0.9%,
P < 0.001).24 This discrepancy may be attributed to the fact that
their analyses were performed in unmatched populations and
therefore their CAS population could be overall sicker than the CEA
cohort and consequently more prone to inferior outcomes.
Another ﬁnding in our study is asymptomatic women had
higher MI rates after CEA (women: 0.75% vs. men: 0.51%,
P ¼ 0.0009) or CAS (women: 0.96% vs. men: 0.28%, P ¼ 0.01).
Interestingly, the CREST trial, which is the only large trial that
assessed sex differences in MI rates, failed to show a gender-related
difference.13 However, it did show equivalent rate of peri-
procedural MI in women regardless of carotid procedure (CAS or
CEA). There is ample evidence in the literature that coronary
disease in women is often underdiagnosed and undertreated and
women are less likely than men to be optimised with adequate
anti-platelet agents, statins and b-blockade.27,28,29 Suboptimal
optimisations and recognition of their coronary risks in women
may explain the higher rate of cardiac complication when
compared to men and lack of cardiac beneﬁt after CAS when
compared to CEA. However, MI does not seem to be a key driver in
the adverse outcomes in mainly asymptomatic patients.13
Our study has limitations. As with all studies of administrative
data sets, there is a potential for coding errors. The comparison of
two different procedures, however, reduces the impact of such
errors, assuming that frequency of coding errors is similar in both
groups.14 Another limitation of administrative databases is the lack
of clinical data, that is, it is impossible to determine the severity of
complications such as transient ischaemic attack (TIA) or stroke.
Because there are no patient identiﬁers in the SPARCS database,
longitudinal follow-upwasnotpossible, and for this reasonwecould
not assess long-term freedom from restenosis, stroke prevention or
survival. We could not study the re-admission rates since each
admission to the hospital counts as a separate encounter and cannot
be related to a previous one as re-admission. The reported in-
hospital mortality or stroke rates are not equivalent to 30-day
peri-procedural event rates. In this context, the interval between
index event and type of revascularisation could not be assessed and
the analysis performed might underestimate the event rate espe-
cially in the CAS cohort.Weusedpropensity score to create balanced
and comparable cohorts for analysis. However, propensity score-
based analysis compared to randomisation can only adjust for
observed covariates and not for unobserved.14 In any case, propen-
sity score matching only reduces the bias, but does not eliminate it.
Besides, the relative paucity for symptomatic patients remains
a limitation as well. Thus, the absence of statistically signiﬁcant
differences regarding symptomatic cohorts despite the clear trend
for more adverse events after CASmay be due to type II error. In this
database, we were unable to assess or match patients who weretreated for restenosis after previous CEA or CAS, contralateral
occlusion, hostile neck or high bifurcation. Protection devices and
anti-platelet therapy could not be matched between the cohorts as
well. Age was used as a continuous variable and all patients in the
matchedcohortswerebetween70and72years old.Despiteall these
limitations, administrative data sets are advantageous bymeasuring
how a speciﬁc therapeutic intervention fares in the community at
large centres and provide cohorts of sufﬁcient size allowing
comparison between sexes and symptomatic and asymptomatic
patients that is not easily attainable in randomised studies.
Conclusions
In the last decade in NYS, more than 90% of patients of both
sexes underwent CAS or CEA due to asymptomatic carotid artery
disease. CEA showed a clear superiority to CAS regarding the in-
hospital outcomes in symptomatic women. However, CAS was not
inferior to CEA in all other cohorts (men regardless symptom-
atology and asymptomatic women). CEA and CAS demonstrated
comparable rates of MI in all cohorts and asymptomatic females
were more prone to MI than males after both procedures. This
study suggests that CAS is not a reasonable treatment option in
symptomatic womenwith carotid artery disease and reinforces the
notion that sex should be taken into account when different carotid
procedures are being considered in different symptom-related
settings.
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